Literature DB >> 9033283

Cyclin D1 expression in invasive breast cancer. Correlations and prognostic value.

P J van Diest1, R J Michalides, L Jannink, P van der Valk, H L Peterse, J S de Jong, C J Meijer, J P Baak.   

Abstract

Cyclin D1 overexpression, detected by standard immunohistochemistry, was correlated with other prognostic variables and its prognostic value was evaluated in a group of 148 invasive breast cancers with long-term follow-up. Overexpression of cyclin D1 (59% of cases) was negatively correlated (chi 2 test) with histological grade (P = 0.0001), mean nuclear area (P = 0.004), mean nuclear volume (P = 0.02), and mitotic activity (P = 0.03) and positively correlated with estrogen receptor (P = 0.0001). There was a strong correlation between cyclin D1 overexpression and histological type (P = 0.0001). Positive cyclin D1 staining was seen in 11 of 13 tubular carcinomas, 3 of 3 mucinous carcinomas, 4 of 4 invasive cribriform carcinomas, and 17 of 20 lobular carcinomas. Of 102 ductal cancers, 52 were positive, and all 6 medullary carcinomas were negative. There were no significant correlations with lymph node status, tumor size, or DNA ploidy. In survival analysis, cyclin D1 overexpression did not provide significant univariate or multivariate prognostic value. In conclusion, cyclin D1 is mainly overexpressed in the well differentiated and lobular types of invasive breast cancer and is strongly associated with estrogen receptor positivity. It is negatively correlated with the proliferation marker mitoses count and with the differentiation markers nuclear area and nuclear volume. However, cyclin D1 overexpression does not seem to have prognostic value in invasive breast cancer when no adjuvant treatment is given.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9033283      PMCID: PMC1858273     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  34 in total

1.  The morphometric prognostic index is the strongest prognosticator in premenopausal lymph node-negative and lymph node-positive breast cancer patients.

Authors:  P J van Diest; J P Baak
Journal:  Hum Pathol       Date:  1991-04       Impact factor: 3.466

2.  Pathologic correlates of survival in 378 lymph node-negative infiltrating ductal breast carcinomas. Mitotic count is the best single predictor.

Authors:  F Clayton
Journal:  Cancer       Date:  1991-09-15       Impact factor: 6.860

3.  Computer assisted efficiency testing of different sampling methods for selective nuclear graphic tablet morphometry.

Authors:  J C Fleege; P J van Diest; J P Baak
Journal:  Lab Invest       Date:  1990-08       Impact factor: 5.662

4.  Rearrangement and overexpression of D11S287E, a candidate oncogene on chromosome 11q13 in benign parathyroid tumors.

Authors:  C L Rosenberg; H G Kim; T B Shows; H M Kronenberg; A Arnold
Journal:  Oncogene       Date:  1991-03       Impact factor: 9.867

5.  D11S287, a putative oncogene on chromosome 11q13, is amplified and expressed in squamous cell and mammary carcinomas and linked to BCL-1.

Authors:  G A Lammie; V Fantl; R Smith; E Schuuring; S Brookes; R Michalides; C Dickson; A Arnold; G Peters
Journal:  Oncogene       Date:  1991-03       Impact factor: 9.867

6.  Thymidine labeling index and Ki-67 growth fraction in lesions of the breast.

Authors:  O W Kamel; W A Franklin; J C Ringus; J S Meyer
Journal:  Am J Pathol       Date:  1989-01       Impact factor: 4.307

7.  DNA index and S-phase fraction and their combination as prognostic factors in operable ductal breast carcinoma.

Authors:  H Joensuu; S Toikkanen; P J Klemi
Journal:  Cancer       Date:  1990-07-15       Impact factor: 6.860

8.  Prognostic factors in axillary lymph node-negative (pN-) breast carcinomas.

Authors:  S Aaltomaa; P Lipponen; M Eskelinen; V M Kosma; S Marin; E Alhava; K Syrjänen
Journal:  Eur J Cancer       Date:  1991       Impact factor: 9.162

9.  A novel cyclin encoded by a bcl1-linked candidate oncogene.

Authors:  T Motokura; T Bloom; H G Kim; H Jüppner; J V Ruderman; H M Kronenberg; A Arnold
Journal:  Nature       Date:  1991-04-11       Impact factor: 49.962

10.  Ki67 immunostaining in primary breast cancer: pathological and clinical associations.

Authors:  N Bouzubar; K J Walker; K Griffiths; I O Ellis; C W Elston; J F Robertson; R W Blamey; R I Nicholson
Journal:  Br J Cancer       Date:  1989-06       Impact factor: 7.640

View more
  48 in total

Review 1.  Cell cycle regulators: mechanisms and their role in aetiology, prognosis, and treatment of cancer.

Authors:  R J Michalides
Journal:  J Clin Pathol       Date:  1999-08       Impact factor: 3.411

2.  Association of RB/p16-pathway perturbations with DCIS recurrence: dependence on tumor versus tissue microenvironment.

Authors:  Agnieszka K Witkiewicz; Dayana B Rivadeneira; Adam Ertel; Jessica Kline; Terry Hyslop; Gordon F Schwartz; Paolo Fortina; Erik S Knudsen
Journal:  Am J Pathol       Date:  2011-07-12       Impact factor: 4.307

3.  Caveolin-1 mutations in human breast cancer: functional association with estrogen receptor alpha-positive status.

Authors:  Tianhong Li; Federica Sotgia; Magalis A Vuolo; Maomi Li; Wan Cai Yang; Richard G Pestell; Joseph A Sparano; Michael P Lisanti
Journal:  Am J Pathol       Date:  2006-06       Impact factor: 4.307

4.  A scoring system for immunohistochemical staining: consensus report of the task force for basic research of the EORTC-GCCG. European Organization for Research and Treatment of Cancer-Gynaecological Cancer Cooperative Group.

Authors:  P J van Diest; P van Dam; S C Henzen-Logmans; E Berns; M E van der Burg; J Green; I Vergote
Journal:  J Clin Pathol       Date:  1997-10       Impact factor: 3.411

5.  Nitric oxide-induced cytostasis and cell cycle arrest of a human breast cancer cell line (MDA-MB-231): potential role of cyclin D1.

Authors:  S Pervin; R Singh; G Chaudhuri
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

Review 6.  Genetically engineered ERα-positive breast cancer mouse models.

Authors:  Sarah A Dabydeen; Priscilla A Furth
Journal:  Endocr Relat Cancer       Date:  2014-05-06       Impact factor: 5.678

7.  The role of E-cadherin/beta-catenin complex and cyclin D1 in head and neck squamous cell carcinoma.

Authors:  Nam Yong Do; Sung Yong Park; Sung Chul Lim
Journal:  Cancer Res Treat       Date:  2004-02-29       Impact factor: 4.679

8.  Correlation of cyclin D1 and Rb gene expression with apoptosis in invasive breast cancer.

Authors:  J S de Jong; P J van Diest; R J Michalides; P van der Valk; C J Meijer; J P Baak
Journal:  Mol Pathol       Date:  1998-02

Review 9.  Cyclin D1 and human neoplasia.

Authors:  R Donnellan; R Chetty
Journal:  Mol Pathol       Date:  1998-02

10.  Ligand-independent recruitment of steroid receptor coactivators to estrogen receptor by cyclin D1.

Authors:  R M Zwijsen; R S Buckle; E M Hijmans; C J Loomans; R Bernards
Journal:  Genes Dev       Date:  1998-11-15       Impact factor: 11.361

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.